Format

Send to

Choose Destination
See comment in PubMed Commons below
Arch Phys Med Rehabil. 2008 Mar;89(3):417-21. doi: 10.1016/j.apmr.2007.11.022.

The role of botulinum toxin type A in the radiation fibrosis syndrome: a preliminary report.

Author information

1
Department of Neurology, Rehabilitation Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. stubblem@mskcc.org

Abstract

OBJECTIVE:

To describe the use of botulinum toxin type A (BTX-A) in radiation fibrosis syndrome (RFS).

DESIGN:

Retrospective case series.

SETTING:

A large tertiary care cancer center.

PARTICIPANTS:

Twenty-three consecutive patients treated for sequelae of RFS with BTX-A.

INTERVENTIONS:

Not applicable.

MAIN OUTCOME MEASURES:

A description of the components of RFS thought to benefit from BTX-A injections and the patient's self-report of benefit from those injections.

RESULTS:

The sequelae of RFS for which BTX-A injection was thought to be indicated include radiation-induced cervical dystonia in 18 (78%), trigeminal nerve or cervical plexus neuralgia in 10 (43%), trismus in 7 (30%), migraine in 3 (13%), and thoracic pain in 1 (4%) patient. Most (87%) patients self-reported benefit from the injections.

CONCLUSIONS:

Initial clinical experience with the use of BTX-A as adjunctive treatment for select neuromuscular and musculoskeletal complications of RFS in a variety of cancer patients has been encouraging. Well-designed prospective studies are needed to clarify the potential beneficial role of BTX-A in specific sequelae of RFS.

PMID:
18295617
DOI:
10.1016/j.apmr.2007.11.022
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center